Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 10:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 6,448 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin to Skin Clear all
Completed Phase 2 Interventional Results available

The Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With Moderately Infected Foot Ulcers

NCT00659646
View directory record Official record
Conditions
Diabetic Foot Ulcer
Interventions
gentamicin-collagen sponge and levofloxacin, Levofloxacin only
Drug
Lead sponsor
Innocoll
Industry
Eligibility
18 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Lakeland, Florida
Source: ClinicalTrials.gov public record
Updated Jan 27, 2022 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

NCT06436183
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
Interventions
Camoteskimab, Placebo
Drug
Lead sponsor
Apollo Therapeutics Ltd
Industry
Eligibility
18 Years to 75 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
30
States / cities
Phoenix, Arizona • Encinitas, California • Fountain Valley, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2025 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 1 Interventional Results available

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

NCT00847886
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
LX3305, LX3305 Placebo, Methotrexate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 3, 2010 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Phase 4 Interventional Results available

Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment

NCT01104662
View directory record Official record
Conditions
Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia, Renal Impairment
Interventions
Vancomycin, Daptomycin, Semi-Synthetic Penicillin
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Azusa, California • Los Angeles, California • Torrance, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 1 Interventional

A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

NCT04045496
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Carcinoma, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Other Solid Tumors
Interventions
JAB-3312
Drug
Lead sponsor
Jacobio Pharmaceuticals Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
4
States / cities
Denver, Colorado • Nashville, Tennessee • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

Open Label Photo-Documentation Study Of BPX-01 Minocycline Gel

NCT02946788
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Minocycline
Drug
Lead sponsor
BioPharmX, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Coral Gables, Florida • Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Not applicable Interventional Results available

Role of Magnetic Resonance Fingerprinting and Quantitative MR Imaging in Breast Cancer

NCT03650803
View directory record Official record
Conditions
Breast Cancer
Interventions
3D MR Fingerprinting scan
Device
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)

NCT01775462
View directory record Official record
Conditions
X-Linked Hypohidrotic Ectodermal Dysplasia
Interventions
EDI200
Drug
Lead sponsor
Edimer Pharmaceuticals
Industry
Eligibility
48 Hours to 14 Days · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
San Francisco, California • Washington D.C., District of Columbia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 30, 2026, 10:21 AM EDT
Not yet recruiting Not applicable Interventional

Safety Study of Microlyte DualGuard

NCT07695688
View directory record Official record
Conditions
Wound Closure, Wound Care
Interventions
Microlyte DualGuard, Allevyn Foam (Standard of Care Control)
Device
Lead sponsor
Imbed Biosciences
Industry
Eligibility
22 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
3
States / cities
Phoenix, Arizona • Washington D.C., District of Columbia • New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 1 Interventional

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

NCT00588003
View directory record Official record
Conditions
Breast Cancer
Interventions
anastrozole, Placebo
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
45 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis

NCT02283762
View directory record Official record
Conditions
Scleroderma, Systemic
Interventions
Riociguat (Adempas, BAY63-2521), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Phase 4 Interventional Results available

Improvement In Scratch Behavior And Sleep In Patients With Atopic Dermatitis

NCT05200403
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2%, Vehicle treatment, Accelerometry device for children, Accelerometry device for adult caregivers
Drug · Device
Lead sponsor
Boston University
Other
Eligibility
3 Months to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 1 Interventional

A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together

NCT00618124
View directory record Official record
Conditions
Solid Tumors, Breast Cancer, Neoplasms
Interventions
SU011248; Capecitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Indianapolis, Indiana • Albuqurque, New Mexico • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2010 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS)

NCT03628924
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Guselkumab dose 1, Guselkumab dose 2, Guselkumab dose 3, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
20
States / cities
Birmingham, Alabama • Largo, Florida • Ocala, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma

NCT00938223
View directory record Official record
Conditions
Melanoma
Interventions
4-peptide and 12-peptide melanoma vaccines
Biological
Lead sponsor
Craig L Slingluff, Jr
Other
Eligibility
18 Years to 85 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 3 Interventional Results available

Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission

NCT02373813
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
etanercept pre-filled syringe subcutaneous injection, Oral methotrexate, Placebo for etanercept subcutaneous injection, Placebo for methotrexate, Folic acid (non-investigational product)
Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
74
States / cities
Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Oct 30, 2026, 10:21 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Prospective Study of Topical Vitamin C (THDA) Versus Topical Vitamin C (THDA) With Acetyl Zingerone

NCT05779280
View directory record Official record
Conditions
Wrinkle, Skin Pigmentation
Interventions
THDA + Acetyl Zingerone Topical Product, THDA
Other
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
30 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2023 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional

Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients

NCT01855880
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque Psoriasis
Interventions
AbGn-168H, placebo
Biological
Lead sponsor
AbGenomics B.V Taiwan Branch
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Little Rock, Arkansas • Rogers, Arkansas • Boynton Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Oct 30, 2026, 10:21 AM EDT
Completed No phase listed Observational

Osteomyelitis: Procalcitonin to Diagnose and Monitor Osteomyelitis

NCT02165579
View directory record Official record
Conditions
Diabetes, Foot Ulcer, Osteomyelitis
Interventions
1 cohort, standard care, observational
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

NCT01593020
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Eribulin, 5-Fluorouracil, Epirubicin, Cyclophosphamide, Doxorubicin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Oct 30, 2026, 10:21 AM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study of Tomographic Optical Breast Imaging (DBT-TOBI) to Monitor Response to Neoadjuvant Therapy

NCT03822312
View directory record Official record
Conditions
Breast Cancer
Interventions
DBT-TOBI, MRI-TOBI
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Terminated Phase 1 Interventional

Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer

NCT00937482
View directory record Official record
Conditions
Male Breast Cancer, Stage IV Breast Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer, Tumors Metastatic to Brain
Interventions
cediranib maleate, whole-brain radiation therapy
Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 8, 2013 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus

NCT03288324
View directory record Official record
Conditions
Cutaneous Lupus, Systemic Lupus Erythematosus
Interventions
Tofacitinib
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years to 45 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
2
States / cities
Cincinnati, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 30, 2026, 10:21 AM EDT
Completed Phase 3 Interventional

Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers

NCT01891760
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
Dermagraft, Profore
Device
Lead sponsor
Shire Regenerative Medicine, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Fresno, California • Mather, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2013 · Synced Oct 30, 2026, 10:21 AM EDT